Physician profile
Mary E Wechter
NPI 1194813493
$3,778.40
in general payments reported to CMS, 2019-2025
33 companies · $144 in 2025
The $144 reported for 2025 was less than what a typical Gynecology provider received nationally (typical 2025 total: $162).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $565 · 2020: $213 · 2021: $1,494 · 2022: $519 · 2023: $461 · 2024: $382 · 2025: $144.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $887 · Education: $99.99.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $887.14 |
| Education | $99.99 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Acessa Health INC. | $993.52 | 2021 | |
| Abbvie INC. | $591.18 | 2019-2023 | Lo Loestrin Fe, Orilissa |
| Hologic Sales and Service, LLC | $281.72 | 2019-2024 | Aptima, Thinprep 2000 Processor |
| Astellas Pharma US INC | $205.42 | 2022-2025 | Veozah |
| Pfizer INC. | $154.89 | 2019-2024 | |
| Myovant Sciences INC. | $152.72 | 2022 | |
| Mayne Pharma Commercial LLC | $151.77 | 2022-2025 | |
| Millicent US INC | $125.36 | 2019-2025 | Intrarosa, Femring, Femlyv |
| Bayer Healthcare Pharmaceuticals INC. | $123.97 | 2019-2025 | |
| Medical Device Business Services, INC. | $119.35 | 2021 | |
| Exeltis, USA INC. | $112.46 | 2021-2025 | Slynd |
| Daiichi Sankyo INC. | $109.19 | 2019-2020 | |
| Sumitomo Pharma America, INC. | $79.40 | 2023 | Myfembree |
| Novo Nordisk INC | $61.61 | 2021 | |
| Lsi Solutions INC | $46.31 | 2021-2024 | Fornisee |
Show all 33 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Shield Therapeutics INC | $44.45 | 2024 | |
| Therapeuticsmd, INC. | $43.76 | 2019-2022 | |
| Evofem Biosciences, INC. | $41.97 | 2021-2022 | |
| Scynexis, INC. | $41.03 | 2022 | |
| Covidien LP | $33.74 | 2019 | |
| Mycovia Pharmaceuticals, INC. | $27.76 | 2023 | Vivjoa |
| Allergan, INC. | $26.50 | 2019-2020 | |
| Dysis Medical, INC. | $25.98 | 2020-2021 | |
| Channel Medsystems, INC. | $25.04 | 2023 | |
| Lupin INC. | $24.87 | 2019 | |
| Organon LLC | $20.11 | 2024 | |
| Duchesnay USA Incorporated | $18.70 | 2019 | |
| Roche Diagnostics Corporation | $18.53 | 2019 | |
| Merck Sharp & Dohme LLC | $17.56 | 2020 | |
| Lilly USA, LLC | $16.82 | 2024 | Zepbound |
| Aroa Biosurgery Incorporated | $16.68 | 2022 | |
| Asensus Surgical, INC. | $13.71 | 2019 | |
| Edwards Lifesciences Corporation | $12.32 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Mary Wechter listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.